{ Patent intelligence }
Patent intelligence
for Business
Development
Ventsuri reads your portfolio, filings and public R&D footprint, then surfaces the acquisition and in-licensing targets that close your gaps. Each one ranked, and each pick explained.
No signup. Runs live on a real portfolio.
Substituted imidazoles as GLP-1 receptor agonists
Long-acting triple glucagon / GLP-1 / GIP conjugate
{ The problem }
Why spend years inventing what you could own next quarter
In-house R&D is the slowest, most expensive path to a market position, and the riskiest. The faster move is to acquire the patent that already works and own the category before a competitor does.
R&D is slow and capital-intensive
A new program burns years and hundreds of millions before it sees a clinic, and most never reach the market. Time and budget you spend rediscovering the science is time a competitor spends owning it.
The breakthrough often already exists
Somewhere across 210M+ patents and 216M+ papers, the asset that closes your gap is already filed, sitting in an academic lab or an early-stage company that would rather sell than scale.
Whoever acquires first owns the market
Patents are winner-take-all. Acquire the right one and you lock out the category; miss it and you license it back later, or watch a rival build the moat you should have owned.
{ How it works }
Millions of sources, ranked for your portfolio
Ventsuri unifies 210M+ patents from 100+ countries with the 216M+ papers, trials and disclosures behind them, tracking each filing through its lifecycle and surfacing the few whose acquisition would change your trajectory.
Unify the global corpus
210M+ patents across 100+ countries, spanning USPTO, EPO, WIPO and JPO, reconciled with the 216M+ literature sources behind them: arXiv, PubMed, grant disclosures and trial registries, in one searchable corpus.
Decompose into structured claims
Claims, methods, results and effect spans pulled from every source, with what was demonstrated separated from what was speculated. Each field carries the citation it came from, so every judgment is auditable.
Track each patent's lifecycle
Citations, licensing moves, assignment changes and the startups quietly building on a filing, surfaced the moment a patent gains strategic weight, not the moment it published.
Match to your portfolio
Candidates ranked against your patents, roadmap and competitive position, each recommendation explaining whether acquiring it closes a gap, blunts a competitor, or shaves years off a program.
{ The payoff }
From a sentence to a defensible shortlist
Describe a gap in plain language. Ventsuri scans the corpus, runs diligence on every candidate, and returns a ranked acquire-or-pass call, with the reasoning to take into your next portfolio review.
Ranked, not retrieved. Targets ordered by fit against your portfolio, strongest first.
Reasoned, not guessed. Every pick explains what it covers, why it fits, and where it's weak.
Auditable, not a black box. Legal status, current owner and the source citation behind every claim.
Viking is a peptide GLP-1 + GIP dual-agonist company, with its entire IP estate sitting at the GLP-1R / GIPR axis.
What they already cover
Peptide Formula I dual-agonists at the GLP-1R / GIPR axis: VK2735, injectable and oral.
The gap
No oral small-molecule GLP-1R modality, and no incretin axes beyond GIP: glucagon, amylin, GDF15, PYY.
Graded against the portfolio's coverage and gaps. Calibrated, not a legal opinion.
{ Who it's for }
Built for pharma teams hunting their next R&D target
Whether you're filling a pipeline gap, scouting in-licensing candidates, or sizing up a competitor's mechanism, Ventsuri surfaces the assets worth taking to your next review, with the reasoning to defend each pick.
Pharma R&D leadership
Find external programs that close a pipeline gap or accelerate an internal one. Search by mechanism, indication or modality and get back ranked patents and papers with the evidence behind each match.
Licensing & business development
Run scouting workflows across every major jurisdiction's filings and the science behind them. Surface in-licensing candidates before they reach a competitive sale process.
Corporate strategy & M&A
Track adjacent therapeutic spaces, competitor portfolios and emerging mechanisms. Spot acquisition targets while they're still in academic labs or early-stage hands.
{ Find your next target }
Your R&D budget should buy targets, not searches
Ventsuri compiles millions of patents, filings and papers into one ranked corpus, so the cost of finding what to license or acquire drops, and more goes to the science that makes the deal pay off.
30-minute walkthrough · no slides, your portfolio